-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 8, 2021, Peking University's School of Life Sciences and Peking University-Tsinghua Life Sciences Joint Center Hu Jiazhi's group published online in Nucleic Acids Research entitled " Global detection of DNA repair outcomes induced by CRISPR-Cas9 " and " In-depth assessment of the PAM compatibility and editing activities of Cas9 variants " two research papers
The development of the CRISPR-Cas9 system for genome editing has changed the way of life science research, and at the same time has brought great potential for the treatment of diseases and the development of biotechnology
Figure 1.
In order to reduce the off-target activity of SpCas9 and broaden its target range, workers in this field have developed a variety of SpCas9 variants
Figure 2.
In summary, the work of these two articles systematically evaluated the DNA repair products in the CRISPR-Cas9 editing process and explained its influence mechanism, suggesting that we inhibit the potential mutagenic danger of non-homologous end joining (NHEJ) during gene editing.
Researcher Hu Jiazhi of Peking University is the corresponding author of the two articles